499 assets in Hepatocellular Carcinoma

Therapeutic assets addressing Hepatocellular Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Tiragolumab Hepatocellular Carcinoma	Hoffmann-La Roche	P3	CCC (55)
Tpst-1120 Hepatocellular Carcinoma	Tempest Therapeutics	P3	CCC (55)
Tti 101 Hepatocellular Carcinoma	Tvardi Therapeutics, Incorporated	P1/2	CCC (55)
Atorvastatin Hepatocellular Carcinoma	Chiayi Christian Hospital	P4	CCC (54)
Babaodan Hepatocellular Carcinoma	Nanfang Hospital, Southern Medical University	P4	CCC (54)
Jnj-54135419 Hepatocellular Carcinoma	The Second Affiliated Hospital of Chongqing Medical University	P4	CCC (54)
Lenalidomide Hepatocellular Carcinoma	Shunda Du	P2	CCC (54)
Mesna Hepatocellular Carcinoma	St. Jude Children's Research Hospital	P2	CCC (54)
Metformin Hepatocellular Carcinoma	Dan Zandberg	P3	CCC (54)
Mitoxantrone Hepatocellular Carcinoma	Fudan University	P2	CCC (54)
Obi 3424 Hepatocellular Carcinoma	Zhejiang Hisun Pharmaceutical Co. Ltd.	P2	CCC (54)
Oxycodone Hepatocellular Carcinoma	The First Affiliated Hospital with Nanjing Medical University	P4	CCC (54)
Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493 Hepatocellular Carcinoma	National Cancer Institute (NCI)	P2	CCC (54)
pf-08634404 Hepatocellular Carcinoma	Pfizer	P2	CCC (54)
pm8002 Hepatocellular Carcinoma	Biotheus Inc.	P2	CCC (54)
Prednisone Hepatocellular Carcinoma	Pfizer	P3	CCC (54)
Recombinant Human Il12/15-Pdl1B Oncolytic Hsv-1 ) Hepatocellular Carcinoma	CNBG-Virogin Biotech (Shanghai) Ltd.	P1/2	CCC (54)
Recombinant Interleukin-12 Hepatocellular Carcinoma	CNBG-Virogin Biotech (Shanghai) Ltd.	P1/2	CCC (54)
Rituximab Hepatocellular Carcinoma	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (54)
Sapanisertib Hepatocellular Carcinoma	National Cancer Institute (NCI)	P2	CCC (54)
Sevoflurane Hepatocellular Carcinoma	Kaohsiung Medical University Chung-Ho Memorial Hospital	P4	CCC (54)
Tenofovir Bis(Isopropyloxycarbonyloxymethyl) Ester Hepatocellular Carcinoma	Qing XIe	P4	CCC (54)
Trametinib Hepatocellular Carcinoma	Second Affiliated Hospital of Guangzhou Medical University	P2	CCC (54)
(+)-Vincristine Hepatocellular Carcinoma	University of Birmingham	P3	CCC (54)
Wgi-0301 Hepatocellular Carcinoma	Zhejiang Haichang Biotech Co., Ltd.	P2	CCC (54)
Budigalimab Hepatocellular Carcinoma	AbbVie	P2/3	CCC (53)
Envafolimab Hepatocellular Carcinoma	Anhui Provincial Hospital	P2	CCC (53)
gpc3-car-t cells Hepatocellular Carcinoma	RenJi Hospital	P1/2	CCC (53)
Guadecitabine Hepatocellular Carcinoma	University of Southern California	P2	CCC (53)
Inkt Cells Hepatocellular Carcinoma	Beijing YouAn Hospital	P2	CCC (53)
Ino 9012 Hepatocellular Carcinoma	Geneos Therapeutics	P1/2	CCC (53)
Mtl-Cebpa Hepatocellular Carcinoma	Mina Alpha Limited	P2	CCC (53)
Palbociclib Hepatocellular Carcinoma	Henan Cancer Hospital	P2	CCC (53)
Tocilizumab Hepatocellular Carcinoma	Takeda	P1/2	CCC (53)
Zoledronate Hepatocellular Carcinoma	Sun Yat-sen University	P3	CCC (53)
Abiraterone Hepatocellular Carcinoma	Exelixis	P3	CCC (52)
Acetylcysteine Hepatocellular Carcinoma	Institute of Liver and Biliary Sciences, India	P2	CCC (52)
Adavosertib Hepatocellular Carcinoma	National Cancer Institute (NCI)	P2	CCC (52)
Bat-1706 (Biosimilar Of Bevacizumab) Hepatocellular Carcinoma	BeiGene	P2	CCC (52)
Bavituximab Hepatocellular Carcinoma	University of Texas Southwestern Medical Center	P2	CCC (52)
Bevacizumab Biosimilar Ql 1101 Hepatocellular Carcinoma	Sun Yat-sen University	P2	CCC (52)
Binimetinib Hepatocellular Carcinoma	National Cancer Institute (NCI)	P2	CCC (52)
Capivasertib Hepatocellular Carcinoma	National Cancer Institute (NCI)	P2	CCC (52)
Cobimetinib Hepatocellular Carcinoma	National Cancer Institute (NCI)	P2	CCC (52)
Dabrafenib Hepatocellular Carcinoma	National Cancer Institute (NCI)	P2	CCC (52)
Dalpiciclib Isetionate Hepatocellular Carcinoma	Sun Yat-sen University	P2	CCC (52)
Dasatinib Hepatocellular Carcinoma	National Cancer Institute (NCI)	P2	CCC (52)
Defactinib Hepatocellular Carcinoma	National Cancer Institute (NCI)	P2	CCC (52)
Fexagratinib Hepatocellular Carcinoma	National Cancer Institute (NCI)	P2	CCC (52)
Gsk-2636771 Hepatocellular Carcinoma	National Cancer Institute (NCI)	P2	CCC (52)

Showing 101 to 150 of 499 assets

PreviousPage 3 of 10Next